These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3530782)

  • 21. Kinetics of ceftazidime during plasmapheresis.
    Bozkurt F; Schollmeyer P; Keller E
    Eur J Clin Pharmacol; 1987; 33(2):197-201. PubMed ID: 3319644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of naproxen in subjects with normal and impaired renal function.
    Anttila M; Haataja M; Kasanen A
    Eur J Clin Pharmacol; 1980 Oct; 18(3):263-8. PubMed ID: 7439246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
    Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is renal function the only determinant in the elimination of ceftazidime?
    Narang PK; Hunter JR
    Rev Infect Dis; 1984; 6(5):732-5. PubMed ID: 6390641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime in the elderly: appropriateness of twice-daily dosing.
    Sirgo MA; Norris S
    DICP; 1991 Mar; 25(3):284-8. PubMed ID: 2028636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():241-5. PubMed ID: 6352626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients.
    Jonsson M; Walder M
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):15-21. PubMed ID: 1563378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.
    Péchère JC; Dugal R
    J Infect Dis; 1976 Aug; 134 Suppl():S118-24. PubMed ID: 972269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.
    Roth S; Naber K; Scheer M; Gruenwaldt G; Lange H
    Eur J Clin Pharmacol; 1976 Sep; 10(5):357-65. PubMed ID: 789084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of ceftazidime in elderly patients and young volunteers.
    Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 1984; 16(3):325-6. PubMed ID: 6387894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis.
    Pechere JC; Dugal R; Pechere MM
    Clin Pharmacokinet; 1978; 3(5):395-406. PubMed ID: 699461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics of teicoplanin in varying degrees of renal function.
    Lam YW; Kapusnik-Uner JE; Sachdeva M; Hackbarth C; Gambertoglio JG; Sande MA
    Clin Pharmacol Ther; 1990 May; 47(5):655-61. PubMed ID: 2140543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetration of ceftazidime into extracellular fluid in patients.
    Hoffstedt B; Walder M
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():289-92. PubMed ID: 19803000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.
    Hedman A; Adan-Abdi Y; Alvan G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1988 Jul; 15(1):57-65. PubMed ID: 3042246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.